Logo
x

Search

Subscribe Now

Sesen Bio

Carisma Therapeutic to Go Public through Reverse Merger with Sesen Bio for CAR-M Therapies

Carisma Therapeutic to Go Public through Reverse Merger with Sesen Bio for CAR-M Therapies

  • September 22, 2022
The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

  • August 16, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.